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Abstract 
Oral squamous cell carcinoma (OSCC) is a lethal disease, with rising incidence. In 
2011, 6,767 new cases and 2,056 deaths occurred in the UK. Cancers are preceded 
by oral potentially malignant disorders (PMD), recognizable mucosal diseases 
harbouring increased, SCC risk offering clinicians a ‘therapeutic window’ to 
intervene. Contemporary practice remains unable to predict lesion behaviour or 
quantify malignant transformation (MT) risk. No clear management guidelines exist 
and the literature cannot determine whether early diagnosis and intervention 
prevents cancer. 773 laser treatments were performed between 1996 and 2014 in 
Newcastle Maxillofacial Surgery and efficacy of intervention examined by reviewing 
clinico-pathological details and clinical outcome for 590 PMD patients followed for a 
mean of 7.3yrs. Histopathology required ‘up-grading’ in 36% on examining excision 
specimens. 74.2% of patients were disease free (DF), younger patients with ‘low-
grade’ dysplasia, whilst 9% exhibited persistent disease and were older with 
proliferative verrucous leukoplakia (PVL). DF status was less likely for 
erythroleukoplakia (p=0.022), ‘high-grade’ dysplasia (p<0.0001) and with lichenoid 
inflammation (P=0.028). In 12%, unexpected OSCC was identified, whilst 4.8% 
transformed to malignancy. Interventional laser surgery facilitates definitive diagnosis 
and treatment, allows early diagnosis of OSCC, identifies progressive disease and 
defines outcome categories. Evidence is lacking that intervention halts 
carcinogenesis. Multi-centre, prospective, RCTs are needed to confirm the efficacy 
of surgery.  
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Introduction 
Oral squamous cell carcinoma (OSCC), probably the commonest head and neck 
malignancy, remains lethal and deforming due to local invasion, oro-facial 
destruction, metastasis to cervical lymph nodes and blood-borne tumour 
dissemination1. In 2011, 6,767 new cases and 2,056 deaths occurred in the UK 
whilst globally OSCC shows rising incidence with prognosis significantly 
compromised by advanced disease and late presentation2. 
The ‘progression model’ for oral carcinogenesis proposes that, following irreversible 
genotypic mutation, phenotypic epithelial disorganisation and dysmaturation changes 
occur which, if allowed to progress, lead to invasive OSCC3. Such features 
preceding cancer are identifiable microscopically and collectively termed dysplasia4. 
In clinical practice, assessment of the degree of dysplastic change is made following 
incision biopsy and classification into mild, moderate or severe categories, according 
to the extent of atypical epithelium5. 
It has been recognized for many years that a spectrum of distinct mucosal 
abnormalities, now termed potentially malignant disorders (PMD) and which 
accompany dysplasia, may be identified clinically, albeit non-specifically, during oral 
examination. There is, therefore, opportunity for early diagnosis and therapeutic 
intervention during this ‘oral pre-cancer window’6. PMD encompasses primarily 
localized lesions such as leukoplakia, erythroplakia and erythroleukoplakia, together 
with progressive multi-focal disorders such as proliferative verrucous leukoplakia 
(PVL)7,8. 
      
PMD identification in a patient does not mean inevitable malignant transformation 
(MT) will occur. Many lesions do not progress, while others spontaneously resolve, 
but it remains impossible in clinical practice to predict behaviour for individual cases. 
Nonetheless, PMD patients remain at increased risk of OSCC9.  
‘Potential malignancy’ is difficult to define so it is unsurprising that previous treatment 
interventions have been non-specific with ill-defined goals and end-points; the few 
clinical trials in the literature concentrate on medical therapies and are compromised 
by small patient numbers and short study durations10. No study has demonstrated 
long-term lesion resolution, reduction in disease incidence or prevention of MT11. 
Arduino et al12 emphasized the need for long term patient studies to improve 
understanding of PMD natural history.   
Lack of insight into PMD progression has resulted in a variety of proposed 
treatments based upon clinicians’ preferences and experience. PMDs are mucosal 
lesions only so do not require the aggressive treatment necessary for removal or 
destruction of invasive cancer. It seems self-evident, therefore, to intervene early to 
excise dysplastic tissue at this ‘pre-invasive’ stage. 
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Interventional laser therapies evolved following demonstrable failure of observational 
and medical treatments and limitations in conventional surgery to treat oral 
PMD13,14,15,16,17. The use of carbon dioxide (CO2) laser facilitates surgical 
management, providing precise excision, full histopathological lesion assessment, 
minimal post-operative morbidity and coordinated patient follow up14,17,18. Whilst 
excision is preferred, a limited role for ablation allows a defocused laser beam to 
destroy small or less dysplastic lesions particularly on gingiva / alveolar sites16.  
Previous PMD treatment studies are limited by small patient numbers and varying 
follow up periods. Detailed, long term analysis of a large, well-defined PMD patient 
cohort undergoing coordinated treatment and follow-up was overdue. 
 
Aims of the Study  
In the absence of national PMD disease statistics or a robust evidence-base for 
treatment, the aims of this study were to profile patient demography and clinico-
pathological data for a patient cohort presenting to a specialist PMD service in North-
East England, to determine clinical outcomes following interventional CO2 laser 
surgery and to assess treatment efficacy and its influence on the progress of oral 
carcinogenesis. 
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Method 
1. Caldicott Approval was obtained from Newcastle University / Newcastle upon 
Tyne Hospitals NHS Foundation Trust to facilitate anonymized, retrospective data 
collection from medical records, operating logs and pathology reports from PMD 
patients treated by the author and attending specialist services at Newcastle Dental 
and Royal Victoria Infirmary hospitals. Inclusion criteria required new, untreated 
single-site PMD confirmed by incision biopsy. Patients with previous or multi-focal 
PMD, and those with a history of OSCC or head and neck radiotherapy were 
excluded.    
2. Patient and Treatment Details. Demographic and clinico-pathological details 
collected from patients undergoing CO2 laser surgery between August 1996 and 
December 2014 comprised:  date of treatment, age and sex, clinical appearance and 
anatomical site of oral lesion, histopathology diagnoses for incision and post-laser 
excision biopsies, follow-up data and any further laser treatment. Clinical outcome 
was determined at the study census date (31 December 2014) unless malignancy 
supervened when this became study exit-point.  
3. Histopathology Diagnoses. Incision biopsies were performed under the direction of 
the first author (PJT) and excision specimens obtained following interventional laser 
treatment as detailed previously14. Laser surgery was carried out by PJT, or by 
colleagues working under direct supervision, within 6 to 12 weeks following incision 
biopsy to avoid disease progression. Formalin-fixed tissue specimens were 
assessed via standardized histopathology examination by oral pathologists at the 
Royal Victoria Infirmary working to agreed diagnostic criteria with peer review and 
consensus grading4. Using the World Health Organization (WHO) classification, 
specimens were graded as mild, moderate or severe dysplasia, carcinoma-in-situ 
(CiS) or OSCC. In addition, presence of hyperkeratosis, lichenoid inflammation (LI), 
or diagnoses of PVL and chronic hyperplastic candidosis (CHC) were recorded.  
4. Clinical Outcome Categories. By reviewing case records, the authors assigned 
patients to one of the following clinical outcome categories: Disease Free (DF), the 
absence of PMD, Further Disease achieving DF status following additional 
intervention (Further/DF), Further Disease persisting despite intervention 
(Further/Persistent) and MT, if OSCC was confirmed by histopathological 
examination.  
5. Statistical Analyses. Descriptive Statistics were used to summarise details of 
patient demography, clinical features and pathological diagnoses, together with 
documentation of treatment interventions, clinical outcome and follow-up data. 
Histopathology diagnoses were treated as categorical variables and testing of 
agreement between incision biopsy and post-laser excision biopsy diagnoses carried 
out using weighted kappa statistics; a coefficient of 1 represented perfect agreement.  
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Clinical Outcomes were stratified as DF or Persistent Disease (further PMD or MT); 
success rates and 95% Confidence Intervals (CI) were calculated. Multivariate 
logistic regression was used to analyse factors potentially prognostic of DF outcome 
(age at first treatment, sex, lesion appearance, anatomical site and histopathology 
data). Relationships between factors were explored using chi-square tests for 
categorical variables, correlation coefficients or logistic regression to check for 
collinearity. Factors were first explored univariately and then a multivariate model 
built using a stepwise procedure until all variables were significant at the 10% level. 
Candidate variables for the initial model were those significant at the 20% level 
univariately. If collinearity was suspected only the most significant univariate 
relationships were included in the model. MT was analysed using univariate Cox 
regression to investigate clinico-pathological variables that might influence time to 
transformation. All statistical analyses were performed using SAS/STAT® 9.3 
software (SAS Institute Inc, Cary, USA). 
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Results 
Table 1 summarizes the study results. 
1. Patient Demography. 590 PMD patients were treated during the 19-year period. 
Mean age at presentation was 59.7 years, with 347 males (59%) and 243 females 
(41%); 513 (87%) were current or ex-smokers and 496 (84%) regularly consumed 
alcohol.  
2. Clinical Features. 468 lesions were leukoplakias, with erythroleukoplakia (99) and 
erythroplakia (23) less common. Floor of mouth and ventro-lateral tongue sites were 
involved in 358 cases.  
3. Histopathology Features. Histopathological grading, based upon the most 
significant diagnosis obtained from either incision or laser excision biopsy showed 
522 lesions (88.5%) exhibited dysplasia or CiS. Incision and post-laser excision 
biopsies were available for direct comparison in 609 cases: in 307 (50%) diagnoses 
agreed, although in 220 (36%) excision specimens were ‘up-graded’ due to more 
severe dysplasia (121 or 20%) or OSCC diagnosis (99 or 16%). In 82 cases (14%), 
excision specimens were less severe than incision samples. Whilst overall kappa 
agreement was deemed moderate at 0.45 (95% CI 0.40 to 0.51), specific agreement 
regarding OSCC diagnosis between incision and excision biopsies was only 0.25 
(95% CI 0.15 to 0.35). 
4. Patient Management. The initial treatment modality was laser excision in 526 
patients (89%) and ablation in 64 (11%). In total, 773 treatments were performed on 
590 patients: 513 (87%) underwent 1 laser surgery, whilst 77 (13%) required repeat 
intervention. The mean number of treatments per patient was 1.2 (Standard 
Deviation 0.6), with a median of 1 (range 1 to 8).  
5. Clinical Outcome.  Mean follow-up was 7.3 years (SD 5.1 years), with a median of 
6 years (range 0 to 19 years). 438 patients (74.2%, 95% CI 70.7 to 77.8%) were DF 
at study census date. 404 patients achieved this immediately following laser surgery, 
whilst an additional 34 required further laser intervention; 77 repeat treatments were 
provided with the mean number to achieve DF 2.26 (range of 2 to 4) and a mean 
time of 32.88 months (range 4 to 130.9 months). Out of 87 patients who required 
repeat treatment, 53 exhibited persistent PMD at census. MT was seen in 99 cases; 
in 71 (12%), OSCC diagnosis was made unexpectedly following histopathological 
examination of laser excision specimens, whilst a further 28 (4.8%) underwent MT 
during follow-up; median time to malignancy was 87.3 months (95% CI 59.9 to 
149.2). Overall, 80 OSCCs were identified at the same site as their PMD precursor 
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whilst 19 arose at new, distinct sites. Erythroleukoplakias were most likely to exhibit 
malignancy (p=0.0019; Fisher’s exact test). 
6. Statistical Analyses.  Univariate logistic regression analyses of clinico-pathological 
features potentially influencing DF status are summarised in Table 2. PVL did not 
meet the 20% criteria for inclusion in the multivariate model and anatomical site was 
sparse and highly correlated to a number of other factors therefore was also 
excluded. The final multivariate model contained lesion appearance (p=0.022), 
dysplasia (p<0.001) and the presence of LI (p=0.028); Table 3. Erythroleukoplakic 
lesions had significantly lower odds of achieving DF status compared with 
leukoplakia (OR 0.51, 95% CI 0.31 to 0.83), whilst the odds of DF status were 
significantly increased for lesions exhibiting mild compared with severe dysplasia 
(OR 2.25, 95% CI 1.27 to 3.98). The likelihood of DF status was reduced for lesions 
exhibiting LI features (OR 0.49, 95% CI 0.26 to 0.93). 28 patients underwent MT, 
with the median time to MT in the cohort 87.3 months (95% CI 59.9 to 149.2); Figure 
1. Univariate Cox regression analysis showed no significant influence of clinico-
pathological variables on MT time, but this could be due to the small number of 
events in the analysis. 
 
Discussion 
1. Introduction. This data set of 590 PMD patients, undergoing standardised and 
coordinated treatment by a single surgeon offers additional insight into the natural 
history of PMD in North-East England, albeit in a defined hospital population. The 
study provides detailed outcome data recorded over a follow-up period of 19 years 
(mean 7.3 years).       
2. Patient Demographics. Demographics confirmed a median patient age of 60 years 
and, with 59% of cases male and 41% female, a 1.4:1 male to female ratio. No 
significant relationships between age/sex and PMD presentation or clinical outcome 
were characterised which is similar to previous analyses14,19,20. Most patients 
regularly smoked tobacco and drank alcohol confirming these as relevant 
aetiological factors in Northern England3. 
3. Clinico-Pathological Features. The majority of PMD lesions were leukoplakias 
arising on the floor of mouth and ventro-lateral tongue, consistent with previous 
observations, probably due to underlying site predisposition to epithelial cell 
dysregulation and carcinogenic influence21,22.  88.5% of lesions in this study 
exhibited dysplasia or CiS, emphasizing the ‘high-risk’ nature of PMD disease in this 
population17. Re-grading of tissue specimens in a research-orientated approach was 
not undertaken as this would not have reflected the ‘real-world’ nature of the study23.  
Whilst the prognostic significance of PMD lesions exhibiting LI (sometimes termed 
lichenoid dysplasias) has proved controversial5,8,24, this study has confirmed that 
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persistent PMD disease is associated with lesions exhibiting LI. Previous clinical 
studies have observed isolated erythroleukoplakic lesions with LI arising at ventro-
lateral tongue sites to be at ‘high risk’ of MT25,26. Whilst oral lichenoid lesions have 
not been routinely followed up continuously, this may be advisable to monitor for 
early cancerous change8.  
 
4. Laser Treatment. Whilst the use of CO2 laser as an effective, low-morbidity PMD 
treatment modality has been documented previously14,16,17,19,20, this study has 
facilitated analysis of laser treatment in the largest patient cohort reported in the 
literature17,27. Advantages of laser include a relatively bloodless surgical field, 
improved intra-operative accuracy, reduced post-operative pain, limited scarring, 
reduced damage to adjacent tissues, low complication rates and the ability to repeat 
treatment14,16,17,18. Laser excisions were performed in 89% of patients distinguishing 
this study from previous publications favouring ablative techniques28, the latter 
disadvantaged by lack of definitive biopsy and repeat application required for 
disease resolution. It is notable that 87% of patients in this study required only 1 
intervention.  
5. Clinical Outcome.  This long-term cohort study has facilitated detailed stratification 
of clinical outcome data, although it is difficult to compare these with other 
publications due to differing diagnostic and clinical decision making, varying 
treatment protocols and inconsistent terminology seen in other papers 15,17,29. 75% of 
study patients were, however, DF at census date confirming a degree of treatment 
efficacy for laser intervention, pertinent because nearly 90% of treated lesions 
exhibited significant dysplasia. In terms of characterisation, DF patients were 
generally younger with mild or moderate dysplasia and no LI. 
Long term clinic follow-up helped distinguish patients DF after further treatment (34 
or 5.8%) from persistent disease despite intervention (53 or 9%). Patients in the 
Further/DF category were younger, developed new lesions at different sites, had less 
severe dysplasia and disease resolved after multiple treatments. In contradistinction, 
Further/Persistent patients were older, commonly had PVL lesions on gingiva, 
alveolus and labial mucosa and underwent ablation rather than excision. 
Traditionally, PVL diagnoses were made late during disease history following 
progressive spread, high recurrence and MT7,30. This study helps emphasise the 
importance of early PVL recognition in specialist PMD clinics, but recognises that 
ablative treatment intervention may have reduced efficacy. 
 
6. Malignant Transformation. MT rates for PMDs vary worldwide with quoted values 
ranging between 0.1 to 40%, and an overall rate estimated at 12%, making it difficult 
to counsel individual patients15,16,17. This study distinguished between 71 cases 
(12%) in which pre-existing OSCCs were discovered upon PMD laser excision and 
28 (4.8%) in which OSCC development occurred post-treatment (4.8%). The 
significance of early OSCC diagnosis is emphasised because all 71 patients were 
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definitively treated by their initial laser intervention. Overall, 80 OSCC cases were 
identified at the same-site as precursor lesions whilst 19 developed at new sites 
during follow-up confirming the need for long-term surveillance post-treatment. 
Recognisable clinico-pathological features associated with MT included an 
erythroleukoplakic appearance, severe dysplasia or CiS in initial biopsies and floor of 
mouth/ventro-lateral tongue sites of origin.  
7. Study Limitations.  This was not a prospective, randomised controlled trial, nor 
was it multi-centre, and it is recognised that clinician bias may have influenced both 
patient recruitment and treatment. Reliance on pre-existing clinical records can be 
problematic because detail and accuracy vary over time.  It was disappointing in this 
study to find incomplete data regarding tobacco and alcohol use during follow-up as 
these confounding factors may influence outcome. We have, however, previously 
observed few changes in tobacco and alcohol use in Newcastle PMD patients 
following treatment19,20. Patient satisfaction and quality of life issues were not 
assessed in this study; these areas of research are important in modern healthcare 
provision and will form an integral part of future, prospective studies31.   
In conclusion, this study has succeeded in providing data on the demographics and 
clinico-pathological profile of PMD disease in North-East England, and has detailed 
long-term clinical outcome following intervention. Optimal treatment requires 
consistent diagnoses, effective intervention and coordinated patient follow-up. Whilst 
these have been demonstrated in this study cohort, we have not demonstrated 
reduction in overall cancer risk, although the early identification and treatment of 
OSCC in 12% of cases probably justifies intervention alone. Whilst further analyses 
of cases with poor clinical outcome (persistent PMD and MT) are warranted, the next 
major phase of research requires prospective, multi-centre trialling, ideally 
internationally, to truly define the efficacy of interventional surgery. 
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Table 1: Patient Demographic, Clinico-Pathological and Outcome Data for Treated 
PMD Patients (Number = 590). 
Age  
Mean (SD) 59.7 (12.6) 
Median (range) 60.0 (23-94) 
Sex  No. (%) 
Male 347 (58.8%) 
Female 243 (41.2%) 
Lesion                                                                              No. (%) 
Leukoplakia 468 (79.3%)  
Erythroleukoplakia  99 (16.8%) 
Erythroplakia 23 (3.9%) 
Site                                                                            No. (%) 
Floor Of Mouth 172(29.2%) 
Lateral Tongue 130 (22.0%) 
Buccal Mucosa 59 (10.0%) 
Palate 57 (9.7%) 
Ventral Tongue 56 (9.5%) 
Labial Commissure 29 (4.9%) 
Fauces / Retromolar Region 26 (4.4%) 
Gingiva 21 (3.6%) 
Alveolus 18 (3.1%) 
Labial Mucosa 11 (1.9%) 
Dorsum of  Tongue 11 (1.9%) 
Histopathology Diagnosis (Most Significant) No. (%) 
Hyperkeratosis 8 (1.4%) 
Hyperkeratosis + Lichenoid Inflammation (LI) 28 (4.8%) 
Chronic Hyperplastic Candidosis 17 (2.9) 
Proliferative Verrucous Leukoplakia (PVL) 15 (2.5%) 
Mild Dysplasia 118 (20.0%) 
Mild Dysplasia + LI 28 (4.7%) 
Mild Dysplasia + PVL 40 (6.8%) 
Moderate Dysplasia 105 (17.8%) 
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Moderate Dysplasia + LI 24 (4.0%) 
Moderate Dysplasia + PVL 15 (2.5%) 
Severe Dysplasia 99 (16.8%) 
Severe Dysplasia + LI 8 (1.4%) 
Severe Dysplasia + PVL 4 (0.7%) 
Carcinoma-in-Situ 81 (13.7%) 
Duration of Follow up* (Years)  
Mean (SD) 7.3 (5.1) 
Median (Range) 6 (0-19) 
Treatment Intervention per Patient  
Mean (SD) 1.2 (0.6) 
Median (Range) 1 (1-8) 
Clinical Outcome   
Disease Free 404 (68.4%) 
Further / Disease Free                                                                    34   (5.8%) 
Further / Persistent Disease                                                                      53   (9.0%) 
Malignant Transformation 99 (16.8%)  
 
*Time from first treatment to 31st Dec 2014 
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Table 2: Univariate Analysis of Clinico-Pathological Factors Influencing Disease Free 
Status   
                                                                       
Factor                       Logistic p-value 
Site 0.001 
Age 0.026 
Sex 0.112 
Lesion <0.001 
Dysplasia 
(None, Mild, Moderate vs Severe) 
                            <0.001 
LI 0.043 
PVL 0.289 
 
 
 
 
Table 3: Final Multivariate Model of Clinico-Pathological Factors Influencing Disease 
Free Status 
  
Effect 
Odds 
Ratio 
Estimate 
95% Wald 
Confidence Limits 
P-value 
Lesion                       EK  vs LK 0.659 0.269 1.619 0.022 
Lesion                      ELK vs LK 0.510* 0.314 0.828* 
Dysplasia            Mild  vs  Severe 2.247* 1.270 3.976* <0.0001 
Dysplasia    Moderate vs Severe 1.693 0.954 3.006 
Dysplasia          None  vs  Severe 0.628 0.369 1.068 
LI                              No vs Yes 0.489* 0.258 0.926 0.028 
 
*Significant at the 5% level 
17 
 
Odds Ratio estimates >1 indicate increased likelihood of DF status, <1 decreased likelihood of DF 
status 
(LK=Leukoplakia; ELK=Erythroleukoplakia; EK=Erythroplakia) 
  
 
 
Figure 1: Kaplan-Meier Analysis plotting Time to Malignant Transformation (months) for PMD 
Precursor Lesions.  
 
 
 
 
 
 
 
